Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exemestane and Cyclophosphamide in Metastatic Breast Cancer
NCT01963481Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Sep 2013
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exemestane and cyclophosphamide in breast cancer, sponsored by NYU Langone Health. Primary endpoint: Progression-free Survival Rate at 3 months. Started Sep 2013; status: completed.
02
Drugs
exemestanecyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01963481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01963481.